The estimated Net Worth of S. Louise Phanstiel is at least $3.25 Million dollars as of 5 August 2021. Ms. Phanstiel owns over 60,000 units of Myriad Genetics stock worth over $2,408,457 and over the last 15 years she sold MYGN stock worth over $440,000. In addition, she makes $399,488 as Independent Chairman of the Board at Myriad Genetics.
Sign up
Ms. Phanstiel MYGN stock SEC Form 4 insiders trading
S has made over 7 trades of the Myriad Genetics stock since 2013, according to the Form 4 filled with the SEC. Most recently she exercised 60,000 units of MYGN stock worth $1,400,400 on 5 August 2021.
The largest trade she's ever made was exercising 60,000 units of Myriad Genetics stock on 5 August 2021 worth over $1,400,400. On average, S trades about 3,597 units every 96 days since 2009. As of 5 August 2021 she still owns at least 91,646 units of Myriad Genetics stock.
You can see the complete history of Ms. Phanstiel stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
S. Louise Phanstiel biography
S. Louise Phanstiel CPA serves as Independent Chairman of the Board of the Company. Ms. Phanstiel is director of Myriad since September 2009, held several important positions at WellPoint, Inc. from 1996 to 2007, including as President, Specialty Products (2003 to 2007), Senior Vice President, Chief of Staff and Corporate Planning in the Office of the Chairman (2000 to 2003), and Senior Vice President, Chief Accounting Officer, Controller, and Chief Financial Officer for all WellPoint, Inc. subsidiaries, including Blue Cross of California (1996 to 2000). Previously, Ms. Phanstiel was a partner at the international services firm of Coopers & Lybrand where she served clients in life and property/casualty insurance, high technology, and higher education. She currently serves on the Board of Directors of Verastem, Inc. and the Stony Brook Foundation. Ms. Phanstiel received a B.A. degree in Accounting from Golden Gate University and is a Certified Public Accountant.
What is the salary of S Phanstiel?
As the Independent Chairman of the Board of Myriad Genetics, the total compensation of S Phanstiel at Myriad Genetics is $399,488. There are 10 executives at Myriad Genetics getting paid more, with R. Bryan Riggsbee having the highest compensation of $3,138,980.
How old is S Phanstiel?
S Phanstiel is 61, she's been the Independent Chairman of the Board of Myriad Genetics since 2020. There are 8 older and 16 younger executives at Myriad Genetics. The oldest executive at Myriad Genetics, Inc. is Walter Gilbert, 87, who is the Independent Vice Chairman of the Board.
What's S Phanstiel's mailing address?
S's mailing address filed with the SEC is 320, Wakara Way, U of U Research Park, Salt Lake City, Salt Lake County, Utah, 84108, United States.
Insiders trading at Myriad Genetics
Over the last 22 years, insiders at Myriad Genetics have traded over $51,783,466 worth of Myriad Genetics stock and bought 61,160 units worth $1,252,955 . The most active insiders traders include Jerry S Lanchbury, Peter D Meldrum, and Arthur H Jr Hayes. On average, Myriad Genetics executives and independent directors trade stock every 18 days with the average trade being worth of $563,312. The most recent stock trade was executed by Heinrich Dreismann on 9 September 2024, trading 10,000 units of MYGN stock currently worth $270,500.
What does Myriad Genetics do?
myriad genetics inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. myriad is focused on three strategic imperatives: maintaining leadership in an expanding hereditary cancer market, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. for more information on how myriad is making a difference, please visit the company's website: www.myriad.com.
What does Myriad Genetics's logo look like?
Complete history of Ms. Phanstiel stock trades at Myriad Genetics and Verastem Inc
Myriad Genetics executives and stock owners
Myriad Genetics executives and other stock owners filed with the SEC include:
-
R. Bryan Riggsbee,
Chief Financial Officer, Executive Vice President, Treasurer -
Bernard Tobin,
President - Myriad Autoimmune -
Jerry Lanchbury,
Chief Scientific Officer -
Paul J. Diaz,
CEO, Pres & Director -
R. Bryan Riggsbee,
Exec. VP, CFO & Treasurer -
Dr. Jerry S. Lanchbury Ph.D.,
Chief Scientific Officer -
Dr. Jerry S. Lanchbury,
Chief Scientific Officer -
Mark S. Verratti,
Pres of Myriad Neuroscience & Autoimmune -
Nicole Lambert,
Chief Operating Officer -
John Henderson,
Independent Director -
S. Louise Phanstiel,
Independent Chairman of the Board -
Dennis Langer,
Independent Director -
Heiner Dreismann,
Independent Director -
Lawrence Best,
Independent Director -
Walter Gilbert,
Independent Vice Chairman of the Board -
Daniel Spiegelman,
Independent Director -
Daniel Skovronsky,
Independent Director -
Colleen Reitan,
Independent Director -
Lee Newcomer,
Independent Director -
Rashmi Kumar,
Independent Director -
Mark Pollack,
Chief Medical Officer -
Gary King,
Executive Vice President - International Operations -
Benjamin Jackson,
Executive Vice President, General Counsel, Secretary -
Mark Verratti,
President - Myriad Neuroscience -
Ralph McDade,
President - Myriad RBM -
Nicole Lambert,
President - Myriad Oncology -
Paul Diaz,
President, Chief Executive Officer, Director -
Pamela Wong,
Chief Legal Officer -
Nathan Smith,
Sr. VP of Investor Relations & Treasury -
Dr. Kevin Richard Haas,
Chief Technology Officer -
Paul Chip Parkinson,
Exec. VP of Reimbursement Strategy -
Jayne Baird Hart,
Exec. VP of HR -
Dr. Clivetty Martinez,
Chief Compliance Officer -
Benjamin Jackson,
Exec. VP, Gen. Counsel & Sec. -
Scott Gleason,
Sr. VP of Investor Relations -
Kevin Richard Haas,
Chief Technology Officer -
Alexander Ford,
Chief Operating Officer -
Kevin Richard Haas,
Chief Technology Officer -
Heinrich Dreismann,
Director -
Richard Wenstrup,
Chief Medical Officer -
Virginia Drosos,
President Assurex Health -
Richard M Marsh,
V.P., General Counsel -
Mark Christopher Capone,
President & C.E.O. -
Samraat S. Raha,
Chief Operating Officer -
Pamela Wong,
Chief Legal Officer -
Walter Lloyd Sanders,
President Myriad Oncology -
Linda S Wilson,
Director -
Mark H Skolnick,
Chief Scientific Officer -
Gerald P. Belle,
Director -
Adrian N Hobden,
President -
W Wayne Laslie,
Chief Operating Officer, MPI -
Robert S Attiyeh,
Director -
Dale A Stringfellow,
Director -
Arthur Hull Jr Hayes,
Director -
Arthur H Jr Hayes,
Director -
William A Iii Hockett,
Vice President -
Gregory C Critchfield,
President -
Jay M Moyes,
Chief Financial Officer -
S George Simon,
Vice President -
Robert Gardner Harrison,
Chief Information Officer -
Ronald S. Rogers,
Exec VP Corp Communications -
James S Evans,
V.P. Finance -
T Craig Benson,
President, Myriad RBM -
Paul Bisaro,
Director -
Eric Santa,
Former Chief Growth Officer -
Paul Parkinson,
Fmr EVP Strategy & Innovation -
Margaret Ancona,
SVP, Chief of Staff -
Dale Muzzey,
Chief Scientific Officer -
Natalie Munk,
Chief Accounting Officer -
Heinrich Dreismann,
Director -
Jayne B. Hart,
See Remarks -
Shereen Solaiman,
Chief People Officer -
Scott J. Leffler,
Chief Financial Officer -
Jennifer Lynne Fox,
Chief Legal Officer